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a  b  s  t  r  a  c  t
Cutaneous  T-cell  lymphoma  (CTCL)  is  a heterogeneous  group  of  rare non-Hodgkin  lymphomas  that  arise
in the  skin.  In  advanced  stages,  CTCL  becomes  systemic  and  is  associated  with  poor  prognosis.  Diagnosis  of
CTCL  and  treatment  of  early-stage  disease  with  topical  therapies  often  occurs  under  the  care  of  a  derma-
tologist.  Community  oncologists  see  few  patients  with  CTCL  due  to direct  referrals  from  dermatologists
to  academic  or lymphoma  specialty  centers.  However,  some  patients  will  continue  to  be  managed  in a
community  setting.  Currently  there  is no evidence-based  stepwise  algorithm  for  treatment  of  patientsomidepsin
istone deacetylase inhibitor
with  CTCL,  and guidelines  suggest  a wide  range  of  systemic  therapies,  including  biologics,  targeted  agents,
and more  traditional  chemotherapies.  To  provide  optimal  care  in  a community  setting,  oncologists  must
become  familiar  with  newer  nonchemotherapeutic  treatment  options.  This  review  highlights  romidepsin,
a  histone  deacetylase  inhibitor  approved  for the  treatment  of  patients  with  CTCL  who  have  received  ≥1
prior  systemic  therapy.
©  2016  The  Author.  Published  by Elsevier  Ireland  Ltd. This  is  an  open  access  article  under  the CCE-mail address: sreddy@stanford.edu
ttp://dx.doi.org/10.1016/j.critrevonc.2016.07.001
040-8428/© 2016 The Author. Published by Elsevier Ireland Ltd. This is an open access a
d/4.0/).BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. CTCL overview and epidemiologyCutaneous T-cell lymphoma (CTCL) is a heterogeneous group of
non-Hodgkin lymphomas (NHL) in which malignant, mature, post-
rticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
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the percentage of body surface area involvement and type(s) of
lesions (Olsen et al., 2011), and palpation of peripheral lymph
node regions and other masses. Appropriate laboratory studies
include complete blood count, assessment of Sézary cells (and
Table 1
ISCL/EORTC Staging System for CTCL and Disease Presentation and Survival by Stage.
Stage Classiﬁcations (Olsen
et al., 2007a)
Presentation by
Stage, n (%) (Agar
et al., 2010)
Median Survival
by Stage, years
(Agar et al., 2010)
IA T1 N0 M0 B0-1 438 (29) 35.5
IB  T2 N0 M0 B0-1 583 (39) 21.5
IIA  T1-2 N1-2 M0 B0-1 40 (3) 15.8
IIB  T3 N0-2 M0 B0-1 167 (11) 4.7
IIIA  T4 N0-2 M0 B0 100 (7) 4.7
IIIB  T4 N0-2 M0 B1 56 (4) 3.4
IVA1 T1-4 N0-2 M0 B2 67 (5) 3.8
IVA2 T1-4 N3 M0 B0-2 37 (3) 2.1
IVB  T1-4 N0-3 M1 B0-2 14 (1) 1.4
CTCL, cutaneous T-cell lymphoma; EORTC, European Organisation for Research and
Treatment of Cancer; ISCL, International Society for Cutaneous Lymphomas; NCI,
National Cancer Institute.
T (skin): T1, limited patch/papule/plaque (<10% body surface area [BSA]); T2, gener-
alized patch/papule/plaque (≥10% BSA); T3, tumors; T4, generalized erythroderma
(≥80% BSA).
N (nodes): N0, no clinically abnormal peripheral lymph nodes; N1, N2, N3, clinically
abnormal peripheral lymph nodes with histopathology Dutch grade 1/NCI LN0-2,
Dutch grade 2/NCI LN3, Dutch grade 3–4/NCI LN4, respectively (clone +/−).
M  (viscera): M0,  no involvement; M1,  visceral involvement.00 S.A. Reddy / Critical Reviews in On
hymic T cells initially arise in the skin (Lansigan et al., 2008). The
ost common type of CTCL is mycosis fungoides (MF) (Criscione
nd Weinstock, 2007; NCCN, 2016), and CTCL is sometimes referred
o by the common subtypes MF  and Sézary syndrome (SS, leukemic
ariant) (NCCN, 2016). Rare non-MF/SS CTCL subtypes and their
reatment vary widely, and it is beyond the scope of this review
o discuss them in detail. NHL accounts for ≈4% of all cancers
iagnosed in the United States (US), with 72,580 estimated new
ases in 2015 (American Cancer Society, 2016) and a US preva-
ence of 569,536 people in 2013 (National Cancer Institute, 2016).
TCL accounts for ≈4% of NHL cases in the US (Criscione and
einstock, 2007; Leukemia and Lymphoma Society, 2016), with
3000 new cases diagnosed per year (American Cancer Society,
016). CTCL typically affects older people, with a median age at
iagnosis reported at 54 years old (Agar et al., 2010), and rates
ncrease exponentially with age (Korgavkar et al., 2013; Imam et al.,
013). However, CTCL does occur in younger people, including chil-
ren (Crowley et al., 1998; Pope et al., 2010). Additionally, there is
 ≈1.5:1 male:female and black:white predominance in CTCL cases
Korgavkar et al., 2013; Imam et al., 2013).
In early stages, CTCL is conﬁned to the skin but can progress
o systemic disease (lymph node, blood, visceral organs), result-
ng in signiﬁcantly reduced survival (Olsen et al., 2007a; Klemke
t al., 2005). Other than patients with stage IA disease, patients
ith CTCL have worse overall survival (OS) than that of age-, sex-,
nd race-matched control populations (Talpur et al., 2012). Median
S for patients with later-stage disease (≥IIB) is <5 years (Agar
t al., 2010). However, the time frame for disease progression can
iffer extensively; some patients will remain in early stages for
ecades, while others progress to later-stage disease (Leukemia and
ymphoma Society, 2016).
. Presentation and diagnosis
Patients with undiagnosed CTCL typically present to a derma-
ologist with the appearances of patches or plaques of unclear
tiology. The time from initial symptoms to diagnosis is often
everal years (Mishra and Porcu, 2011) because early-stage CTCL
requently resembles more benign conditions, such as eczema or
soriasis, and may  initially show improvement with topical corti-
osteroids or other common therapies for these conditions (Parker
nd Bradley, 2006; Zackheim and McCalmont, 2002). Early symp-
oms of CTCL are typically dry skin and/or a rash (red, dark, or
ight skin patches), often with itching (pruritus) (Leukemia and
ymphoma Society, 2016). However, visible skin changes as a
esult of CTCL vary widely and may  include scaly red rash or
iscolored patches in areas not usually exposed to sun; thin, red-
ened, eczema-like rash; thickened scaly, red skin (or plaques)
r psoriasis-like rash; and/or erythroderma (skin redness, often
ith scaling) (Leukemia and Lymphoma Society, 2016). Upon
arly presentation, pathology, appearance of skin lesions and clin-
cal presentation may  not support the diagnosis. In time, the
linicopathologic picture will lead to a diagnosis of CTCL. Both
rythroderma and the appearance of tumors should increase the
ndex of suspicion of an alternative diagnosis. The visibility of skin
hanges as a result of CTCL can affect patients both physically and
motionally, impacting their quality of life (QoL) (Leukemia and
ymphoma Society, 2016; Parker and Bradley, 2006). Addition-
lly, even in early-stage disease, patient QoL can be signiﬁcantly
mpacted by pruritus—often described as debilitating as a result of
iscomfort and inability to sleep or perform daily activities (Parker
nd Bradley, 2006; Meyer et al., 2010; Demierre, 2010; Ahern et al.,
012; Vij and Duvic, 2012; Demierre et al., 2006).
Patients also frequently experience skin infections as a result
f breakdown of the skin at lesion sites (Leukemia and Lymphoma/Hematology 106 (2016) 99–107
Society, 2016; Parker and Bradley, 2006). Unmanageable infections
can result in sepsis and death in patients with CTCL (Axelrod et al.,
1992; Tsambiras et al., 2001). Maintaining a low index of suspi-
cion for potential skin infections and secondary sepsis is important.
Obtaining skin culture of wounds and other areas as indicated is of
vital importance and provides guidance for therapy, particularly
for patients treated with frequent antibiotics. Oncologists should
also have a low index of suspicion for viral infection and appropri-
ate skin cultures should be taken. Although viral infection is less
common, proper management to prevent it is essential. Skin care,
especially for those with skin breakdown, can be very complicated,
and collaborating with dermatologists and a multidisciplinary cen-
ter will aid in dealing with these varied presentations (Poligone and
Querfeld, 2015). The importance of aggressive management of sec-
ondary skin issues cannot be understated because it will generally
reduce death and morbidity from sepsis/skin infection. Further-
more, appropriate management of skin infections can clarify during
the skin exam what is and is not disease.
Diagnosis of CTCL is often conﬁrmed under the direction of
a dermatologist, and requires a series of tests and procedures,
including physical examination and history of treatments to the
skin lesions, skin biopsies along with clinicopathologic correla-
tion (histopathology, immunohistochemistry, molecular analysis),
lymph node biopsies—particularly in the absence of deﬁnitive skin
diagnosis, and assessment of peripheral blood for the presence of
malignant T-cells (Sézary cells) (Jawed et al., 2014a). A narrative
review of the diagnosis of CTCL was recently published (Jawed et al.,
2014a).
3. Staging and prognosis
Staging of CTCL is based on disease involvement in the skin,
lymph nodes, blood, or visceral organs (Table 1) (Olsen et al., 2007a).
Workup to determine staging should include at a minimum a com-
plete physical examination, including skin exam, assessment ofB  (blood): B0, absence of signiﬁcant blood involvement (Sézary cells <5% of periph-
eral blood lymphocytes, clone +/−); B1, low tumor burden (Sézary cells >5% of
peripheral blood lymphocytes without meeting criteria for B2, clone +/−); B2, high
blood tumor burden (Sézary cells ≥1000/L of peripheral blood lymphocytes with
clone +).
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-cell receptor gene rearrangement studies of peripheral blood
ymphocytes if blood involvement is suspected), comprehensive
etabolic panel, and lactate dehydrogenase (a negative prognos-
ic factor for survival when elevated (Agar et al., 2010; Talpur
t al., 2012)). Imaging studies (chest/abdominal/pelvic contrast-
nhanced computed tomography [CT] or integrated whole body
ositron emission tomography-CT) are indicated for assessment of
ystemic disease in patients with ≥T2 (Table 1), large cell trans-
ormation, folliculotropic MF,  palpable adenopathy, or abnormal
aboratory studies and other indicators of systemic disease (NCCN,
016).
As expected, survival is decreased with advancing clinical stage
Agar et al., 2010). In a large multidisciplinary cutaneous lymphoma
linic in the United Kingdom, 1502 patients diagnosed with CTCL
etween 1980 and 2009 had a median survival range of 35.5 years
or stage IA disease to 1.4 years for stage IVB disease (Table 1).
ther negative prognostic factors include performance status (PS),
dvanced age, large cell transformation, and folliculotropic MF  sub-
ype (Agar et al., 2010; Talpur et al., 2012).
. Overview of the treatment of CTCL
No treatments for CTCL, topical or systemic, have been shown
o prolong patient survival, although improved survival is implied
y treatments that control advanced-stage disease. Aggressive
reatment of infections and related supportive care is also likely
ontributing to improvements in patient outcomes. This assertion
hould be prefaced by stating that few rigorous studies have been
onducted, in part due to lack of effective national and interna-
ional clinical trial study groups functioning outside the purview
f industry-sponsored studies. While all studies are biased to
ome degree, it can be useful to have results prospectively repli-
ated in different settings (eg, cooperative groups, international
tudy groups, industry sponsored, community driven). Although
ccasional independent prospective studies are conducted by orga-
izations such as the European Organisation for Research and
reatment of Cancer (EORTC) (Whittaker et al., 2012), such stud-
es are rare in the United States (US). Most data are of lower quality
nd do not involve appropriate controls or randomization, and ade-
uate quality control of skin assessments are lacking. Despite this,
 number of industry-sponsored single-arm studies have provided
easonable efﬁcacy data. The National Comprehensive Cancer Net-
ork (NCCN) is a reliable US source for recommendations based on
he application of these data.
Because no treatments for CTCL have been shown to signif-
cantly prolong patient survival, current treatment is aimed at
rolonging time to progression, reducing disease burden, and pre-
erving or enhancing patient QoL (Jawed et al., 2014b). Treatment
f early-stage (IA-IIA) CTCL typically involves skin-directed thera-
ies (NCCN, 2016; Leukemia and Lymphoma Society, 2016), often
dministered under the care of a dermatologist (Aires, 2016).
reatment options recommended by the NCCN include topical cor-
icosteroids, topical chemotherapy (mechlorethamine [commonly
eferred to as nitrogen mustard], carmustine), phototherapy (ultra-
iolet B [UVB], narrow band UVB for patch/thin plaques, psoralen
lus ultraviolet A [PUVA] for thicker plaques), local radiation, topi-
al retinoids (bexarotene or tazarotene), topical imiquimod, or total
kin electron beam therapy (TSEBT; reserved for severe skin symp-
oms or generalized thick plaque or tumor disease, or for patients
ith poor responses to other topical therapies) (NCCN, 2016).
Selection of topical therapies for patients with CTCL is highlyndividualized and has been reviewed elsewhere in detail (NCCN,
016; Jawed et al., 2014b). The only topical agents speciﬁcally
pproved by the US Food and Drug Administration (FDA) for use
n patients with CTCL are bexarotene (TARGRETIN, 2013) and/Hematology 106 (2016) 99–107 101
mechlorethamine (VALCHLOR, 2012). Patients with more advanced
disease (stage ≥ IIB) typically receive systemic treatment with or
without topical treatment (NCCN, 2016; Leukemia and Lymphoma
Society, 2016). Due to the prolonged survival of patients with early-
stage disease, it is worth noting that emphasis on quality of life
should guide therapy. Systemic therapies should be carefully con-
sidered since many patients with early-stage disease may  only
require topical therapies (NCCN, 2016; Jawed et al., 2014b; Prince
et al., 2009). In the setting of known efﬁcacy data, the lower adverse
event (AE) proﬁle of an agent should be weighed when considering
the early use of systemic agents. More diffuse skin involvement and
advanced skin lesions with or without negative prognostic factors
would warrant the use of systemic agents and/or TSEBT. It is worth
noting that in order to receive TSEBT, a patient is usually required
to have at least minimal functional status (eg, Eastern Cooperative
Oncology Group PS ≥2).
Patients are best served by at least a consultation by a multidis-
ciplinary team that includes dermatologists, oncologists, radiation
oncologists, and supporting staff, and the NCCN guidelines recom-
mend that patients with CTCL be treated at specialty centers (NCCN,
2016; Poligone and Querfeld, 2015). These centers can conﬁrm the
diagnosis, provide up-to-date data on disease management, and
both discuss with the patient the options for and provide access to
stem cell transplant and clinical trials for advanced disease. How-
ever, many patients with CTCL will receive at least some care in a
community setting for a variety of reasons. These patients should
be encouraged to make at least 1 visit to a specialty center to con-
ﬁrm pathology and preliminary treatment approaches, after which
ongoing care could be managed in the community depending on
the location of the patient. It is the best interest of the patient that
specialty centers and community centers work together to reduce
stressors such as travel.
The NCCN guidelines for the treatment of MF/SS suggest a
wide range of systemic therapies, including biologics, targeted
therapies, and more traditional chemotherapies (NCCN, 2016).
However, as noted previously, a rigorous evidence-based step-
wise algorithm does not exist for treatment selection due to lack
of comparative data, and its absence leads to a wide variation
in use of these agents. Treatment regimens should be individ-
ualized to each patient. In the US, only bexarotene (retinoid),
denileukin diftitox (fusion protein), romidepsin (class 1 spe-
ciﬁc histone deacetylase [HDAC] inhibitor (Bradner et al., 2010)),
and vorinostat (pan-HDAC inhibitor (Bradner et al., 2010)) are
approved by the FDA for the treatment of relapsed/refractory
CTCL (ISTODAX (romidepsin), 2014; TARGRETIN, 2013; ONTAK
(denileukin diftitox), 2008; ZOLINZA (vorinostat), 2015). How-
ever, denileukin diftitox has not been available since 2012, and a
new formulation is under clinical development (NCCN, 2016). In
advanced disease, treatment with biologics or targeted therapies is
generally preferred prior to traditional chemotherapy. In settings
warranting chemotherapy, single-agents are generally preferred
over multi-agent regimens (NCCN, 2016; Prince et al., 2009), and
preferred agents include doxorubicin and gemcitabine. Multi-agent
chemotherapy is generally reserved for patients without response
to several prior systemic therapies, including those with visceral
and refractory nodal disease, or as pretransplant regimen (NCCN,
2016; Prince et al., 2009). Regimens used are typically those that
have shown efﬁcacy in B-cell lymphomas or Hodgkin lymphoma;
however, responses seen in patients with CTCL are typically brief
and can carry high risks of infection and/or myelosuppression,
especially if skin infection is not appropriately managed. The selec-
tive use of chemotherapy is supported by a classic randomized
study (Kaye et al., 1989).
Combinations of skin-directed and systemic therapies may be
used to maximize responses in the skin (Leukemia and Lymphoma
Society, 2016). Partnering with a dermatologist to manage skin dis-
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advanced patients even prior to this trial. For advanced patients,
long-term control with a single agent in their treatment lifetime
is unusual. This, combined with the fact that controls (eg, placebo,
Table 2
Key Baseline Characteristics in Phase 2 Studies of Romidepsin for the Treatment
of Relapsed/Refractory CTCL (ISTODAX (romidepsin), 2014; Piekarz et al., 2009;
Whittaker et al., 2010).
Pivotal Study
(N = 96)
NCI Study
(N = 71)
Male, n (%) 59 (61) 48 (68)
Age, median (range), years 57 (21–89) 57 (28–84)
ECOG performance status, n (%)
0 49 (51) 16 (23)
1  47 (49) 45 (63)
2  0 (0) 10 (14)
Disease stage, n (%)
IA 0 (0) 1 (1)
IB 15 (16) 6 (9)
IIA 13 (14) 2 (3)
IIB 21 (22) 14 (20)
III  23 (24) 9 (13)
IVA 24 (25) 27 (38)
IVB 0 (0) 12 (17)
Blood involvement, n (%)a 37 (39) NR
Moderate-to-severe pruritus, n (%)b 65 (68) NR
Prior skin-directed therapies, median
(range), n
2 (0–6) 1 (0–3)
Prior systemic therapies, median
(range), n
2 (1–8) 2 (0–7)
Note: Where data differed slightly between the package insert and pivotal02 S.A. Reddy / Critical Reviews in On
ase and skin-related complications is important whether or not
ombination therapy is being used. Even with systemic therapy
nly, skin appearance may  worsen due to malignant cell death or
anageable side effects—and for those clinicians with less exper-
ise, skin changes may  be confused with disease progression. Most
atients with CTCL will receive multiple treatment regimens over
he course of their disease (Horwitz et al., 2008). Systemic treat-
ent options for patients with CTCL have been reviewed in detail
lsewhere (NCCN, 2016; Jawed et al., 2014b). Many patients with
TCL also require supportive care, most often to manage their pru-
itus or to avoid or treat skin infections (NCCN, 2016).
When assessing skin disease burden, the importance of treating
he infectious component with therapies guided by careful bacterial
nd, where appropriate, viral cultures cannot be overemphasized.
his degree of skin surveillance is not typical in an oncology practice
ut is worth keeping in mind. The rest of this review will focus
n one reasonable option approved by the FDA. Due to scarcity of
ystemic options, appropriate clinical trials should be considered
n patients with heavily pretreated disease.
. Romidepsin
The epigenetic modifying therapy romidepsin, a structurally
nique, potent, bicyclic class 1 selective HDAC inhibitor (Bradner
t al., 2010; Tan et al., 2010; Bolden et al., 2006), is approved by
he FDA for the treatment of CTCL in patients who have received at
east 1 prior systemic therapy and for the treatment of patients
ith peripheral T-cell lymphoma who have received at least 1
rior therapy (ISTODAX (romidepsin), 2014). Altered expression,
eregulation, and mutations of HDAC genes have been implicated
n various cancers (New et al., 2012). HDAC inhibitors such as
omidepsin result in anticancer effects, including interference with
ell turnover, decreased cell motility and angiogenesis, increased
ell death, and cell differentiation (Bolden et al., 2006; New et al.,
012; Khan and La Thangue, 2012; Marsoni et al., 2008). Vari-
us HDAC inhibitors have been investigated that differ in potency,
DAC selectivity, gene regulation, and nonhistone protein targets
Bradner et al., 2010; New et al., 2012; Khan and La Thangue,
012). In addition to romidepsin, 2 other HDAC inhibitors have
een approved by the FDA for the treatment of T-cell lymphomas.
orinostat has been approved to treat patients with CTCL who have
ad at least 2 prior systemic therapies, and belinostat has been
pproved to treat patients with relapsed or refractory peripheral
-cell lymphoma (PTCL) (ZOLINZA (vorinostat), 2015; BELEODAQ
belinostat), 2014).
.1. Efﬁcacy and safety of romidepsin in relapsed/refractory CTCL
At the National Cancer Institute (NCI), a phase 1 trial of patients
ith various cancers (N = 37) demonstrated the maximum toler-
ted dose (MTD) of romidepsin was 17.8 mg/m2 as a 4-h infusion
n days 1 and 5 of 21-day cycles (Sandor et al., 2002). Four patients
ith T-cell lymphoma were enrolled; all 3 with CTCL achieved
artial responses (PR) with romidepsin, and 1 with PTCL had a
omplete response (CR) (Piekarz et al., 2001). Dose-limiting tox-
cities included nausea and vomiting, which led to routine use of
ntiemetics beginning at the 3.5 mg/m2 dose (Sandor et al., 2002).
 separate phase 1 study of patients with advanced cancers (N = 33)
emonstrated similar results with a slightly different dosing sched-
le (Marshall et al., 2002). The reported MTD  of romidepsin in that
tudy was 13.3 mg/m2 as a 4-h infusion on days 1, 8, and 15 of
8-day cycles (Marshall et al., 2002).
FDA approval of romidepsin for the treatment of
elapsed/refractory CTCL was based on results from the/Hematology 106 (2016) 99–107
pivotal (GPI-04-0001) and NCI (NCI 1312) phase 2, single-arm,
multicenter studies (ISTODAX (romidepsin), 2014; Piekarz et al.,
2009; Whittaker et al., 2010). The NCI study also enrolled patients
with relapsed/refractory PTCL (Piekarz et al., 2011), which have not
been described here. In both studies, patients were treated at the
FDA-approved dose of 14 mg/m2 as a 4-h infusion on days 1, 8, and
15 of 28-day cycles. In the NCI study, the ﬁrst 3 patients received
dosing based on results of the phase 1 NCI study (18 mg/m2 on days
1 and 5 of 21-day cycles); however, the protocol was  then amended
based on improved tolerability (Piekarz et al., 2009). Both studies
used rigorous investigator assessments that examined responses
across disease compartments (skin, lymph, blood, viscera). Histor-
ically, response criteria for CTCL have been inconsistently deﬁned
(NCCN, 2016; Olsen et al., 2011), with some studies, such as the
pivotal trial for vorinostat, primarily assessing response only in
the skin (Olsen et al., 2007b). Recently, the International Society
for Cutaneous Lymphomas, United States Cutaneous Lymphoma
Consortium, and Cutaneous Lymphoma Task Force of the EORTC
have published consensus guidelines for patients with CTCL for
a standard composite assessment that incorporates responses
in the skin, lymph nodes, blood, and viscera (Olsen et al., 2011);
decisions to stop treatment should not be made based on skin
assessments alone. Key endpoints in both romidepsin studies
included objective response rate (ORR: CR + PR), time to response,
duration of response, and safety (Piekarz et al., 2009; Whittaker
et al., 2010). Reduction in pruritus was  also systematically studied
in the pivotal study, and thus, concomitant anti-itch medications,
including steroids and antihistamines, were not allowed to affect
the impact of romidepsin (Whittaker et al., 2010; Kim et al.,
2013).
Patients in both studies tended to be heavily pretreated with
mostly advanced disease (Table 2). Administration of multiple
treatments (both systemic and topical) are standard for mostmanuscripts, package insert data are shown.
ECOG, Eastern Cooperative Oncology Group; NR, not reported.
a Includes patients with >5% of lymphocytes as Sézary cells.
b As measured using patient-assessed 100-mm visual analogue scale. Moderate
was  deﬁned as 30–69 mm and severe as 70–100 mm.
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Table  3
Key Efﬁcacy Data in Phase 2 Studies of Romidepsin for the Treatment of
Relapsed/Refractory CTCL (Piekarz et al., 2009; Whittaker et al., 2010).
Pivotal Study
(N = 96)
NCI Study
(N = 71)a
All patients, n (%)
ORR 33 (34) 24 (34)
CR  6 (6) 4 (6)
Patients with stage ≥IIB disease, n (%)
ORR 26 (38) 18 (29)
CR  5 (7) 4 (7)
Time to response, median (range), months
All responders 2 (1–5) 2 (1–6)
Patients who  achieved CR 4 (1–7) NR
Duration of response, median (range), months 15 (<1+ to 20+) 14 (1–76+)
Time to progression, median (range), months 8 (<1+ to 22+) 15 (NR)
Note: conﬁdence intervals were not reported for either study.
CR, complete response; CTCL, cutaneous T-cell lymphoma; NR, not reported; ORR,
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Table 4
Most Common (regardless of causality, ≥5% in either study) Grade 3/4 Adverse
Events in Phase 2 Studies of Romidepsin for the Treatment of Relapsed/Refractory
CTCL (ISTODAX (romidepsin), 2014).
Grade 3/4 Adverse Events, n (%) Pivotal Study
(N = 102)
NCI Study
(N = 83)
Any 36 (35) 68 (82)
Lymphopenia 0 31 (37)
Infections 11 (11) 27 (33)
Neutropenia 4 (4) 22 (27)
Leukopenia 0 18 (22)
Anemia 3 (3) 13 (16)
Asthenia/fatigue 8 (8) 12 (14)
Thrombocytopenia 0 12 (14)
Vomiting 1 (1) 8 (10)
Hypophosphatemia 0 8 (10)
Dermatitis/exfoliative dermatitis 1 (1) 7 (8)
Hypermagnesemia 0 7 (8)
Hyperuricemia 0 7 (8)
Nausea 3 (3) 5 (6)bjective response rate; PTCL, peripheral T-cell lymphoma.
a A recent analysis of patients from the NCI study (CTCL and PTCL) included 13
dditional patients with CTCL and reported similar outcomes (Bates et al., 2015).
ctive comparator) are lacking make any efﬁcacy estimates approx-
mate. Responses to romidepsin were observed across disease
tages, and response rates were similar in each study (Table 3)
Piekarz et al., 2009; Whittaker et al., 2010). In the pivotal study,
esponse rates in various patient subtypes were also assessed: 34%
n patients with prior chemotherapy (n = 74), 35% in patients with
rior bexarotene or denileukin diftitox (n = 37), 30% in patients
ho had ≥ 2 prior systemic therapies (n = 44), 45% in patients with
utaneous tumors (n = 20), and 60% in patients with folliculotropic
isease involvement (n = 10) (Whittaker et al., 2010; Foss et al.,
014a). In both studies, responses were also seen across disease
ompartments (skin, lymph nodes, blood, viscera) (Piekarz et al.,
009; Whittaker et al., 2010; Kim et al., 2015). In the pivotal study,
2% of patients with blood involvement (n = 37) had a response,
ncluding 2 with CR, and rapid and sustained decreases in Sézary
ell counts were observed (Whittaker et al., 2010); in the NCI study,
 of the 4 patients who achieved CR had SS, 2 of whom remained
n CR at 26 and 63 months (Piekarz et al., 2009); in a later analy-
is, 1 patient with SS remained in CR 10+ years after ﬁrst remission
Bates et al., 2015).
Responses were typically rapid, with a median of 2 months to
rst response in both trials (Piekarz et al., 2009; Whittaker et al.,
010). Median time to CR in the pivotal study was  4 months, indi-
ating that continued treatment may  lead to deeper responses
Whittaker et al., 2010). Responses were often durable, with a
edian duration of response of 15 and 14 months at the latest
ollow-up in the pivotal and NCI studies, respectively (Piekarz et al.,
009; Whittaker et al., 2010; Bates et al., 2015), and the longest
esponse was ongoing at 10+ years in the NCI study (Bates et al.,
015). Notably, patients treated with romidepsin do not receive
xed programs with ﬁnite duration (as is common with chemother-
py) and should continue treatment as long as they continue to
eneﬁt from and tolerate the drug (ISTODAX (romidepsin), 2014).
In the pivotal study, 60 of 65 patients (92%) with moderate to
evere pruritus at baseline (at least 30 mm on a 100-mm patient-
ssessed visual analogue scale) reported a reduction in their itch
Whittaker et al., 2010; Kim et al., 2013). For all patients, the mean
hange was −29 mm,  and a clinically meaningful reduction in pru-
itus (CMRP, ≥30-mm decrease for 2 consecutive treatment cycles)
as seen in 43% of patients with moderate to severe pruritus at
aseline. The median duration of CMRP was 6 months (range, 1+
o 21+ months), and CMRP was observed in both objective respon-
ers (17/26, 65%) and nonresponders (11/39, 28%) (Whittaker et al.,
010; Kim et al., 2013).
The most common AEs in patients with relapsed/refractory
TCL treated with romidepsin included gastrointestinal distur-Pruritus 0 5 (6)
Hypocalcemia 0 5 (6)
bances, hematologic toxicities, clinical chemistry abnormalities,
asthenic conditions, and infections (all types pooled) (ISTODAX
(romidepsin), 2014; Piekarz et al., 2009; Whittaker et al., 2010).
The majority of AEs were reported as grade 1/2. Despite the use
of concomitant antiemetics, grade 1/2 nausea was  reported in the
majority of patients in both studies. Additionally, although grade
3/4 dysgeusia was  not reported (15% and 40% of patients in piv-
otal and NCI studies, respectively, had grade 1/2), even low-grade
dysgeusia can impact patients’ QoL. The most common grade 3/4
AEs are shown in Table 4. Rates of AEs were generally higher in the
NCI study because all abnormalities were reported as AEs, regard-
less of clinical signiﬁcance. In both studies, infections (all types
pooled) were the most common type of serious AE (SAE) reported
(ISTODAX (romidepsin), 2014). However, the majority of all infec-
tions reported were not drug-related and were likely a result of
increased risk due to disease state (including compromised skin
integrity) or the impact of prior therapies (Foss et al., 2014b). Dis-
continuations due to AEs occurred in 21% and 11% of patients in
the pivotal and NCI studies, respectively (ISTODAX (romidepsin),
2014). Events leading to discontinuation in ≥2% of patients in
either study included infection (all types pooled), fatigue, dyspnea,
QT prolongation, and hypomagnesemia (ISTODAX (romidepsin),
2014). There were no cumulative toxicities reported with long-
term romidepsin treatment (Foss et al., 2014b).
5.1.1. Recommendations
Data from phase 2 studies indicate that patients with CTCL can
have durable clinical responses to romidepsin regardless of dis-
ease stage or disease compartment involved—including patients
with blood involvement, who typically present a therapeutic chal-
lenge (ISTODAX (romidepsin), 2014; Piekarz et al., 2009; Whittaker
et al., 2010; Kim et al., 2015). Patients with pruritus may experience
beneﬁt from romidepsin even in the absence of a clinical response
(Whittaker et al., 2010; Kim et al., 2013). Thus, clinicians could
consider keeping patients with disease stabilization and signiﬁ-
cant pruritus relief on romidepsin treatment or consider initiating
romidepsin treatment in patients with early-stage disease and pro-
found pruritus. This should be done with caution and if other
modalities for pruritus fail, because romidepsin requires frequent
infusions, which can be burdensome for patients. Data indicate
that extended dosing of romidepsin can be tolerated in responding
patients (ISTODAX (romidepsin), 2014; Foss et al., 2014b). How-
ever, patients should be instructed to report signs of infection,
including fever, signiﬁcant fatigue, shortness of breath, or bleeding
(ISTODAX (romidepsin), 2014). Although data are lacking, granulo-
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yte colony-stimulating factor could be used on a case-by-case basis
etween treatment cycles if necessary to avoid treatment delays or
eductions. Patients should be instructed to stay hydrated to help
anage nausea, and dysgeusia should be actively managed to min-
mize its impact on QoL, despite the fact that these AEs are typically
rade 1/2 with romidepsin.
.2. Cardiac safety of romidepsin
Electrocardiogram (ECG) abnormalities have been reported with
ome HDAC inhibitors, including romidepsin (Marsoni et al., 2008;
olife et al., 2007; Kristeleit et al., 2005), and a class effect had
een suggested (Molife et al., 2007). However, to my  knowledge
ystematic studies of the cardiac safety of HDAC inhibitors have
een performed only with romidepsin. In a phase 1 study, reversible
CG changes without evidence of myocardial damage were noted
eginning at the 3.5 mg/m2 dose—the same dose at which pro-
hylactic antiemetics were introduced (Sandor et al., 2002). As
 result, the practices of routine cardiac evaluation, exclusion of
atients with known signiﬁcant cardiac abnormalities, and prophy-
actic antiemetic administration before each romidepsin dose were
ncorporated into phase 2 trials (Piekarz et al., 2009; Whittaker
t al., 2010).
Changes in ECG parameters have been noted with use of
ome antiemetics, including commonly used 5-hydroxytryptamine
 receptor agonists such as ondansetron (Navari and Koeller,
003; Keefe, 2002; FDA Drug Safety Communication, 2014). Using
ata from a phase 1 bioavailability trial, a cardiac postmarket-
ng study examined changes in QTc from pre-antiemetic and
ost-antiemetic/preromidepsin baselines (Godfrey et al., 2011).
ven at exposures over 2-fold higher than the approved dos-
ng of 14 mg/m2 via 4-h IV infusion, romidepsin did not have
oncentration-dependent effects on the QTc interval and clini-
ally insigniﬁcant changes in QTc at the approved dosing were
xaggerated due to transient increases in heart rate and use of
Tc-prolonging antiemetic premedication (Godfrey et al., 2011).
Additionally, the need for electrolyte supplementation is com-
on  for patients with T-cell lymphoma (Noonan et al., 2013;
organ et al., 2002), and levels in the normal range were required in
he pivotal and supportive romidepsin studies (Piekarz et al., 2009;
hittaker et al., 2010). Electrolyte supplementation is important
ecause hypomagnesemia and hypokalemia are associated with
CG abnormalities (El-Sherif and Turitto, 2011) and are known risk
actors for cardiac arrhythmias (Peacock et al., 2010; Del Gobbo
t al., 2013; Santoro et al., 2008; Osadchii, 2010). In the NCI study,
or example, replacement of potassium and/or magnesium was
eeded to achieve normal levels in 92% of patients prior to ≥1
omidepsin dose (Noonan et al., 2013).
In the pivotal study in CTCL (N = 96), prolonged QT and corrected
T (QTc) were reported as AEs in 3 and 2 patients, respectively.
owever, ECG values returned to baseline within 24 h and were not
ssociated with functional cardiovascular changes or symptoms
Whittaker et al., 2010). In the NCI study, asymptomatic T-wave
attening or ST-segment depression were reported in over half of
atients, but were not associated with impaired myocardial func-
ion (note: in this study all ECG T-wave changes were reported
s AEs, regardless of clinical signiﬁcance) (Piekarz et al., 2009).
ntensive cardiac monitoring of the ﬁrst 42 patients enrolled in
he NCI study (n = 24 CTCL, n = 18 PTCL) showed that romidepsin
as not associated with myocardial damage or impaired cardiac
unction (Piekarz et al., 2006). A later ECG analysis of 131 patients
n the NCI study (n = 84 CTCL, n = 47 PTCL) conﬁrmed the cardiac
afety of romidepsin while asserting the need for consistent elec-
rolyte replacement in patients with T-cell lymphoma (Noonan
t al., 2013). A mean heart rate increase of 11 beats per minute/Hematology 106 (2016) 99–107
following romidepsin was  reported, with no evidence of increased
arrhythmia (Noonan et al., 2013).
In summary, systematic studies of the cardiac safety of
romidepsin have demonstrated that despite previous concerns
regarding ECG changes with HDAC inhibitors, treatment with
romidepsin appears to lead to clinically insigniﬁcant changes in
QTc that were exaggerated by transient increases in heart rate and
concomitant antiemetic administration.
5.2.1. Recommendations
Caution should be exercised when administering romidepsin
with prophylactic antiemetics, some of which have been associated
with ECG abnormalities (Navari and Koeller, 2003; Keefe, 2002).
During romidepsin treatment, potassium and magnesium levels
should be kept within the normal range (ISTODAX (romidepsin),
2014; Noonan et al., 2013), and transient heart rate increases
associated with romidepsin should be considered during patient
selection and monitoring (ISTODAX (romidepsin), 2014; Noonan
et al., 2013). Appropriate cardiac monitoring, including baseline
and periodic ECGs, should be considered in patients with congeni-
tal long QT syndrome, patients with a history of signiﬁcant cardiac
disease, or patients taking any medications that could lead to sig-
niﬁcant QT prolongation (ISTODAX (romidepsin), 2014).
5.3. Additional considerations for use of romidepsin
5.3.1. Use in speciﬁc populations
Age, sex, or race (white or black) did not appear to inﬂuence
the pharmacokinetics (PK) of romidepsin (ISTODAX (romidepsin),
2014). Administration in women who are pregnant should be
avoided because of the potential to cause fetal harm. Because
it is not known whether romidepsin is excreted in human
milk, as a precaution women  should not nurse while receiving
romidepsin treatment. No overall differences in safety and efﬁcacy
of romidepsin were seen in clinical trials with patients > 65 years
vs ≤ 65 years, but the safety and efﬁcacy of romidepsin has not
been established in pediatric patients. Mild hepatic impairment
or mild to severe renal impairment did not signiﬁcantly inﬂu-
ence romidepsin PK. Patients with moderate or severe hepatic
impairment or end-stage renal disease should be treated with cau-
tion because the effects on romidepsin PK are unknown (ISTODAX
(romidepsin), 2014).
5.3.2. Drug interactions
Romidepsin is metabolized by CYP3A4 and therefore cau-
tion should be taken when coadministering with strong CYP3A4
inhibitors or inducers (ISTODAX (romidepsin), 2014). When
romidepsin is coadministered with strong CYP3A4 inhibitors
(eg, ketoconazole, itraconazole, clarithromycin, atazanavir, indi-
navir, nefazodone, nelﬁnavir, ritonavir, saquinavir, telithromycin,
voriconazole), patients should be monitored for toxicity related
to increased romidepsin exposure. Use of potent CYP3A4
inhibitors (eg, rifampin, dexamethasone, carbamazepine, pheny-
toin, rifabutin, rifapentine, phenobarbital, St John’s wort) should
be avoided when possible (ISTODAX (romidepsin), 2014). Patients
who are concurrently receiving romidepsin and warfarin or its
derivatives should have careful monitoring for possible potentia-
tion of anticoagulation effects or elevated international normalized
ratio. Romidepsin is a substrate of the efﬂux transporter P-
glycoprotein and caution should be exercised when concurrently
administering romidepsin and P-glycoprotein inhibitors because
increased romidepsin concentrations are likely.5.3.3. Romidepsin dosing
As discussed earlier in this paper, potassium and magnesium
should be in the normal range before each romidepsin administra-
S.A. Reddy / Critical Reviews in Oncology
Table  5
Romidepsin Dose Modiﬁcation Due To Adverse Events (ISTODAX (romidepsin),
2014).
Nonhematologic toxicities (except alopecia)
Grade 2 or 3 toxicity Treatment delay until toxicity returns
to grade ≤1 or baseline, then treatment
may  be restarted at 14 mg/m2
Recurring grade 3
toxicity after dose
delay, or any grade 4
toxicity
Treatment delay until toxicity returns
to grade ≤1 or baseline, then dose
should be permanently reduced to
10 mg/m2
Recurring grade 3/4
toxicity after dose
reduction
Treatment discontinuation
Hematologic toxicities
Grade 3/4 neutropenia
or thrombocytopenia
Treatment delayed until ANC
≥1.5 × 109/L and platelet count
≥75 × 109/L or baseline, then
treatment may  be restarted at
14 mg/m2
Grade 4 febrile
(≥38.5 ◦C) neutropenia
or thrombocytopenia
that requires platelet
Treatment delay until cytopenia
returns to grade ≤1 or baseline, then
dose should be permanently reduced
to 10 mg/m2
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The author takes full responsibility for the content of thistransfusion
NC, absolute neutrophil count.
ion (this can be achieved through electrolyte supplementation),
nd the use of prophylactic antiemetics is recommended
efore each dose in all patients (ISTODAX (romidepsin), 2014).
omidepsin is administered at 14 mg/m2 as a 4-h intravenous infu-
ion on days 1, 8, and 15 of 28-day cycles as long as the patient
ontinues to beneﬁt from and tolerate the drug. Dose reductions
r interruptions may  be necessary in the event of hematologic or
onhematologic toxicities (Table 5) (ISTODAX (romidepsin), 2014).
n the pivotal study of romidepsin in patients with relapsed or
efractory CTCL (N = 96), patients who had dose reductions or inter-
uptions due to AEs were still able to achieve durable remissions
Kim et al., 2016).
In the pivotal phase 2 study of romidepsin for the treatment
f relapsed/refractory PTCL, prolonged responses in some patients
ed to a protocol amendment to allow for (but not mandate) main-
enance dosing of 2 doses per 28-day cycle for patients treated
or ≥ 12 cycles. After at least 24 cycles, patients who had received
aintenance dosing for ≥ 6 cycles can have their dosage further
educed to 1 dose per 28-day cycle (Coifﬁer et al., 2014). However,
his dosing was not used in the pivotal or the NCI study for patients
ith relapsed or refractory CTCL. A smaller study (N = 47) of patients
ith CTCL did suggest that long-term responders to treatment with
omidepsin may  beneﬁt from maintenance dosing (every other
eek, once monthly, or every 6 weeks). However, there is no cur-
ent guidance on how and when to reduce romidepsin in patients
ith prolonged responses (Martinez-Escala et al., 2016). The afore-
entioned are reasonable options based on the available data but,
s noted, the potential for reduction in dosing schedule practices
ay  vary widely based on clinical considerations and side effects.
.3.4. Warnings and precautions
Based on AEs reported in clinical trials, patients should be
onitored for thrombocytopenia, neutropenia, lymphopenia, and
nemia during treatment with romidepsin, and dose should be
odiﬁed as necessary (ISTODAX (romidepsin), 2014). Infections
ncluding pneumonia and sepsis can occur in patients treated with
omidepsin and may  be more likely to occur in patients who
ave previously received extensive or intensive chemotherapy. As
reviously stated, patients with congenital long QT syndrome, a
istory of signiﬁcant cardiac disease, or patients taking any medi-
ations that could lead to signiﬁcant QT prolongation should have
ppropriate cardiac monitoring, including baseline and periodic/Hematology 106 (2016) 99–107 105
ECGs, and potassium and magnesium should be within the normal
range before each romidepsin dose (ISTODAX (romidepsin), 2014).
Patients with advanced-stage disease and/or a high tumor burden
should be monitored for tumor lysis syndrome, which occurred
in 1% of patients with tumor stage CTCL (ISTODAX (romidepsin),
2014). Also, pregnancy should be avoided as there are no adequate
and well-controlled studies of romidepsin in pregnant women
(ISTODAX (romidepsin), 2014).
6. Conclusions
For most patients, current treatment of CTCL (MF/SS) is aimed at
prolonging time to progression, reducing disease burden, and pre-
serving or enhancing patient quality of life (Jawed et al., 2014b). For
some patients with advanced CTCL, most of who die of their dis-
ease, stem cell transplant may  have curative potential and provide
long term disease control, though randomized controlled studies
are needed (Schlaak et al., 2013). In hopes of adding to current
effective agents such as romidepsin, many new therapies for CTCL
are under investigation in clinical trials, including agents such as
brentuximab vedotin and mogamulizumab. Romidepsin is an effec-
tive single-agent therapy that results in durable responses in some
patients with relapsed/refractory CTCL (ISTODAX (romidepsin),
2014; Piekarz et al., 2009; Whittaker et al., 2010; Bates et al., 2015).
Responses to romidepsin are seen across disease stages with activ-
ity in all disease compartments (skin, lymph nodes, blood, viscera),
including in patients with SS (Piekarz et al., 2009; Whittaker et al.,
2010; Kim et al., 2015). In addition, romidepsin results in clinically
meaningful reduction in pruritus in both clinical responders and
nonresponders (Whittaker et al., 2010; Kim et al., 2013). Patients
who tolerate romidepsin can remain on treatment as long as they
continue to experience beneﬁt (ISTODAX (romidepsin), 2014; Foss
et al., 2014b).
Community oncologists see few patients with CTCL due to its
rarity and direct referrals from dermatologists to specialty cen-
ters. For example, in a survey of 100 US-based medical oncologists
assessing prescribing experiences with newer oncologic drugs, only
49% had prescribed romidepsin for T-cell lymphoma, and only 31%
were very conﬁdent about prescribing it (Love et al., 2013). To
provide optimal care for patients in a community setting, it is
vital for doctors to become familiar with newer nonchemother-
apy treatment options for CTCL. Patients with CTCL are best served
under the care of a multidisciplinary team that includes oncolo-
gists and dermatologists, particularly at one of the many T-cell
lymphoma specialty centers, but for many patients travel can be
burdensome and obtaining some therapies locally may  be war-
ranted. For those treated in the community, providers should
consider partnering with specialty centers when possible for ongo-
ing guidance regarding patient management. Romidepsin, as well
as other nonchemotherapy options, can be given successfully in
a community setting, as community oncologists are familiar with
management of side effects.
Conﬂict of interest statement
Dr. Reddy has nothing to disclose.
Acknowledgmentsmanuscript, but thanks William Ho, PhD (MediTech Media), for pro-
viding medical editorial assistance. Financial support for medical
editorial assistance was provided by Celgene Corporation.
1 cology
R
A
A
A
A
A
B
B
B
B
C
C
C
D
D
D
E
F
F
F
G
H
I
I
J
J
K
K
K
K06 S.A. Reddy / Critical Reviews in On
eferences
gar, N.S., Wedgeworth, E., Crichton, S., Mitchell, T.J., Cox, M.,  Ferreira, S., et al.,
2010. Survival outcomes and prognostic factors in mycosis fungoides/Sézary
syndrome: validation of the revised International Society for Cutaneous
Lymphomas/European Organisation for Research and Treatment of Cancer
staging proposal. J. Clin. Oncol. 28, 4730–4739.
hern, K., Gilmore, E.S., Poligone, B., 2012. Pruritus in cutaneous T-cell lymphoma:
a  review. J. Am.  Acad. Dermatol. 67, 760–768.
ires, D.J., 2016. Cutaneous T-cell lymphoma: a dermatologist’s perspective, http://
www.clfoundation.org/online-learning-center/disease/ctcl/cutaneous-t-cell-
lymphoma-dermatologist-s-perspective (accessed 06.06.16).
merican Cancer Society, 2016. Cancer facts & ﬁgs, http://www.cancer.org/acs/
groups/content/@research/documents/document/acspc-047079.pdf (accessed
06.06.16).
xelrod, P.I., Lorber, B., Vonderheid, E.C., 1992. Infections complicating mycosis
fungoides and Sezary syndrome. JAMA 267, 1354–1358.
ELEODAQ (belinostat) [package insert]. Irvine, CA : Spectrum Pharmaceuticals,
Inc. 2014.
ates, S.E., Eisch, R., Ling, A., Rosing, D., Turner, M.,  Pittaluga, S., et al., 2015.
Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic
implications from clinical and correlative data. Br. J. Haematol. 170, 96–109.
olden, J.E., Peart, M.J., Johnstone, R.W., 2006. Anticancer activities of histone
deacetylase inhibitors. Nat. Rev. Drug Discov. 5, 769–784.
radner, J.E., West, N., Grachan, M.L., Greenberg, E.F., Haggarty, S.J., Warnow, T.,
et  al., 2010. Chemical phylogenetics of histone deacetylases. Nat. Chem. Biol. 6,
238–243.
oifﬁer, B., Pro, B., Prince, H.M., Foss, F., Sokol, L., Greenwood, M., et al., 2014.
Romidepsin for the treatment of relapsed/refractory peripheral T-cell
lymphoma: pivotal study update demonstrates durable responses. J. Hematol.
Oncol. 7, 11.
riscione, V.D., Weinstock, M.A., 2007. Incidence of cutaneous T-cell lymphoma in
the United States, 1973–2002. Arch. Dermatol. 143, 854–859.
rowley, J.J., Nikko, A., Varghese, A., Hoppe, R.T., Kim, Y.H., 1998. Mycosis
fungoides in young patients: clinical characteristics and outcome. J. Am.  Acad.
Dermatol. 38, 696–701.
el Gobbo, L.C., Imamura, F., Wu,  J.H., de Oliveira Otto, M.C., Chiuve, S.E.,
Mozaffarian, D., 2013. Circulating and dietary magnesium and risk of
cardiovascular disease: a systematic review and meta-analysis of prospective
studies. Am.  J. Clin. Nutr. 98, 160–173.
emierre, M.F., Gan, S., Jones, J., Miller, D.R., 2006. Signiﬁcant impact of cutaneous
T-cell lymphoma on patients’ quality of life: results of a 2005 National
Cutaneous Lymphoma Foundation Survey. Cancer 107, 2504–2511.
emierre, M.,  2010. Mycosis fungoides and Sezary syndrome: the burden of
pruritus. Commun. Oncol. 7, 399–404.
l-Sherif, N., Turitto, G., 2011. Electrolyte disorders and arrhythmogenesis. Cardiol.
J.  18, 233–245.
DA Drug Safety Communication: abnormal heart rhythms may be associated with
use  of Zofran (ondansetron) 2014.
oss, F.M., Duvic, M.,  Lerner, A., Rook, A., Whittaker, S., Kim, E.J., et al., 2014a.
Responses to romidepsin in patients with cutaneous T-cell lymphoma (CTCL)
with tumors and/or folliculotropic involvement. J. Clin. Oncol. 32 (abstract
8575).
oss, F., Coifﬁer, B., Horwitz, S., Pro, B., Prince, H.M., Sokol, L., et al., 2014b.
Tolerability to romidepsin in patients with relapsed/refractory T-cell
lymphoma. Biomark Res. 2 (16).
odfrey, C.J., Cabell, C.H., Balser, B., Wolfson, J., Nichols, J., Burris, H.A., 2011.
Exposure-QTc response analysis of class 1 selective histone deacetylase
inhibitor romidepsin. Blood 118 (abstract 2680).
orwitz, S.M., Olsen, E.A., Duvic, M.,  Porcu, P., Kim, Y.H., 2008. Review of the
treatment of mycosis fungoides and Sézary syndrome: a stage-based approach.
J.  Natl. Compr. Canc. Netw. 6, 436–442.
STODAX (romidepsin) [package insert]. Summit, NJ : Celgene Corporation, 2014.
mam,  M.H., Shenoy, P.J., Flowers, C.R., Phillips, A., Lechowicz, M.J., 2013. Incidence
and survival patterns of cutaneous T-cell lymphomas in the United States.
Leuk. Lymphoma 54, 752–759.
awed, S.I., Myskowski, P.L., Horwitz, S., Moskowitz, A., Querfeld, C., 2014a. Primary
cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): Part I.
Diagnosis: clinical and histopathologic features and new molecular and
biologic markers. J. Am.  Acad. Dermatol. 70, 205.e1-e16.
awed, S.I., Myskowski, P.L., Horwitz, S., Moskowitz, A., Querfeld, C., 2014b. Primary
cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome): Part II
Prognosis, management, and future directions. J. Am.  Acad. Dermatol. 70,
223.e1-17.
aye, F.J., Bunn Jr., P.A., Steinberg, S.M., Stocker, J.L., Ihde, D.C., Fischmann, A.B.,
et  al., 1989. A randomized trial comparing combination electron-beam
radiation and chemotherapy with topical therapy in the initial treatment of
mycosis fungoides. N. Engl. J. Med. 321, 1784–1790.
eefe, D.L., 2002. The cardiotoxic potential of the 5-HT(3) receptor antagonist
antiemetics: is there cause for concern. Oncologist 7, 65–72.
han, O., La Thangue, N.B., 2012. HDAC inhibitors in cancer biology: emerging
mechanisms and clinical applications. Immunol. Cell Biol. 90, 85–94.
im, Y.H., Demierre, M.F., Kim, E.J., Lerner, A., Rook, A.H., Duvic, M., et al., 2013.
Clinically meaningful reduction in pruritus in patients with cutaneous T-cell
lymphoma treated with romidepsin. Leuk. Lymphoma 54, 284–289./Hematology 106 (2016) 99–107
Kim, E.J., Kim, Y.H., Rook, A.H., Lerner, A., Duvic, M.,  Reddy, S., et al., 2015. Clinically
signiﬁcant responses achieved with romidepsin across disease compartments
in patients with cutaneous T-cell lymphoma. Leuk. Lymphoma 56, 2847–2854.
Kim, Y.H., Kim, E.J., Rook, A.H., Lerner, A., Robak, T., Becker, J., et al., 2016.
Responses to romidepsin in patients with relapsed/refractory cutaneous T-cell
lymphoma and dose modiﬁcation: subanalysis of the pivotal phase 2 study.
T-Cell Lymphoma Forum (abstract CTCL16 3).
Klemke, C.D., Mansmann, U., Poenitz, N., Dippel, E., Goerdt, S., 2005. Prognostic
factors and prediction of prognosis by the CTCL Severity Index in mycosis
fungoides and Sézary syndrome. Br. J. Dermatol. 153, 118–124.
Korgavkar, K., Xiong, M.,  Weinstock, M.,  2013. Changing incidence trends of
cutaneous T-Cell lymphoma. JAMA Dermatol. 149, 1295–1299.
Kristeleit, R., Fong, P., Aherne, G.W., de Bono, J., 2005. Histone deacetylase
inhibitors: emerging anticancer therapeutic agents? Clin. Lung Cancer 7 (Suppl
1),  S19–30.
Lansigan, F., Choi, J., Foss, F.M., 2008. Cutaneous T-cell lymphoma. Hematol. Oncol.
Clin. North Am.  22, 979–996.
Leukemia and Lymphoma Society, 2016. Cutaneous T-cell lymphoma facts, https://
www.lls.org/sites/default/ﬁles/ﬁle assets/FS5 Cutaneous%20T-
Cell%20Lymphoma 2014 Final.pdf (accessed 06.06.16).
Love, N., Anderson, K.C., Flaherty, K., Kantarjian, H.M., Lynch, T.J., O’Shaughnessy, J.,
et  al., 2013. Medical oncologists’ clinical experiences and comfort levels with
20  recently approved agents. J. Clin. Oncol. 31 (Suppl. 17570).
Marshall, J.L., Rizvi, N., Kauh, J., Dahut, W.,  Figuera, M.,  Kang, M.H., et al., 2002. A
phase I trial of depsipeptide (FR901228) in patients with advanced cancer. J.
Exp. Ther. Oncol. 2, 325–332.
Marsoni, S., Damia, G., Camboni, G., 2008. A work in progress: the clinical
development of histone deacetylase inhibitors. Epigenetics 3, 164–171.
Martinez-Escala, M.E., Kuzel, T.M., Kaplan, J.B., Petrich, A., Nardone, B., Rosen, S.T.,
et  al., 2016. Durable responses with maintenance dose-sparing regimens of
romidepsin in cutaneous T-Cell lymphoma. JAMA Oncol.
Meyer, N., Paul, C., Misery, L., 2010. Pruritus in cutaneous T-cell lymphomas:
frequent, often severe and difﬁcult to treat. Acta Derm. Venereol. 90, 12–17.
Mishra, A., Porcu, P., 2011. Early CTCL diagnosis, a (miR)age no more. Blood 118,
5717–5718.
Molife, R., Fong, P., Scurr, M.,  Judson, I., Kaye, S., de Bono, J., 2007. HDAC inhibitors
and cardiac safety. Clin. Cancer Res. 13, 1068.
Morgan, M.,  Maloney, D., Duvic, M.,  2002. Hypomagnesemia and hypocalcemia in
mycosis fungoides: a retrospective case series. Leuk. Lymphoma 43,
1297–1302.
NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin’s Lymphomas.
V.3.2016.
National Cancer Institute, 2016. Surveillance, Epidemiology, and End Results
Program. SEER Stat Fact Sheets: non-Hodgkin lymphoma, http://seer.cancer.
gov/statfacts/html/nhl.html (accessed 06.06.16).
Navari, R.M., Koeller, J.M., 2003. Electrocardiographic and cardiovascular effects of
the 5-hydroxytryptamine3 receptor antagonists. Ann. Pharmacother. 37,
1276–1286.
New, M., Olzscha, H., La Thangue, N.B., 2012. HDAC inhibitor-based therapies: can
we  interpret the code. Mol. Oncol. 6, 637–656.
Noonan, A.M., Eisch, R.A., Liewehr, D.J., Sissung, T.M., Venzon, D.J., Flagg, T.P., et al.,
2013. Electrocardiographic studies of romidepsin demonstrate its safety and
identify a potential role for KATP channel. Clin. Cancer Res. 19, 3095–3104.
ONTAK (denileukin diftitox) [package insert]. Woodcliff Lake, NJ : Eisai Inc., 2008.
Olsen, E., Vonderheid, E., Pimpinelli, N., Willemze, R., Kim, Y., Knobler, R., et al.,
2007a. Revisions to the staging and classiﬁcation of mycosis fungoides and
Sezary syndrome: a proposal of the International Society for Cutaneous
Lymphomas (ISCL) and the cutaneous lymphoma task force of the European
Organization of Research and Treatment of Cancer (EORTC). Blood 110,
1713–1722.
Olsen, E.A., Kim, Y.H., Kuzel, T.M., Pacheco, T.R., Foss, F.M., Parker, S., et al., 2007b.
Phase IIb multicenter trial of vorinostat in patients with persistent,
progressive, or treatment refractory cutaneous T-cell lymphoma. J. Clin. Oncol.
25, 3109–3115.
Olsen, E.A., Whittaker, S., Kim, Y.H., Duvic, M.,  Prince, H.M., Lessin, S.R., et al., 2011.
Clinical end points and response criteria in mycosis fungoides and Sezary
syndrome: a consensus statement of the International Society for Cutaneous
Lymphomas, the United States Cutaneous Lymphoma Consortium, and the
Cutaneous Lymphoma Task Force of the European Organisation for Research
and Treatment of Cancer. J. Clin. Oncol. 29, 2598–2607.
Osadchii, O.E., 2010. Mechanisms of hypokalemia-induced ventricular
arrhythmogenicity. Fundam. Clin. Pharmacol. 24, 547–559.
Parker, S.R., Bradley, B., 2006. Treatment of cutaneous T-cell lymphoma/mycosis
fungoides. Dermatol. Nurs. 18:566 (70), 573–575.
Peacock, J.M., Ohira, T., Post, W.,  Sotoodehnia, N., Rosamond, W.,  Folsom, A.R.,
2010. Serum magnesium and risk of sudden cardiac death in the
Atherosclerosis Risk in Communities (ARIC) Study. Am.  Heart J. 160, 464–470.
Piekarz, R.L., Robey, R., Sandor, V., Bakke, S., Wilson, W.H., Dahmoush, L., et al.,
2001. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the
treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood
98, 2865–2868.Piekarz, R.L., Frye, A.R., Wright, J.J., Steinberg, S.M., Liewehr, D.J., Rosing, D.R., et al.,
2006. Cardiac studies in patients treated with depsipeptide, FK228, in a phase
II trial for T-cell lymphoma. Clin. Cancer Res. 12, 3762–3773.
Piekarz, R.L., Frye, R., Turner, M.,  Wright, J.J., Allen, S.L., Kirschbaum, M.H., et al.,
2009. Phase II multi-institutional trial of the histone deacetylase inhibitor
cology
P
P
P
P
S
S
S
T
T
T
is  interested in medical evidence and statistics and its interpretation by physicians
and other scientiﬁc collaborators. He is interested in the quality of clinical trials,
clinical endpoints and especially translational trials in Oncology and their relation-S.A. Reddy / Critical Reviews in On
romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J.
Clin. Oncol. 27, 5410–5417.
iekarz, R.L., Frye, R., Prince, H.M., Kirschbaum, M.H., Zain, J., Allen, S.L., et al., 2011.
Phase II trial of romidepsin in patients with peripheral T-cell lymphoma. Blood
117, 5827–5834.
oligone, B., Querfeld, C., 2015. Management of advanced cutaneous T-cell
lymphoma: role of the dermatologist in the multidisciplinary team. Br. J.
Dermatol. 173, 1081–1083.
ope, E., Weitzman, S., Ngan, B., Walsh, S., Morel, K., Williams, J., et al., 2010.
Mycosis fungoides in the pediatric population: report from an international
childhood registry of cutaneous lymphoma. J. Cutan. Med. Surg. 14, 1–6.
rince, H.M., Whittaker, S., Hoppe, R.T., 2009. How I treat mycosis fungoides and
Sézary syndrome. Blood 114, 4337–4353.
andor, V., Bakke, S., Robey, R.W., Kang, M.H., Blagosklonny, M.V., Bender, J., et al.,
2002. Phase I trial of the histone deacetylase inhibitor, depsipeptide
(FR901228, NSC 630176), in patients with refractory neoplasms. Clin. Cancer
Res.  8, 718–728.
antoro, A., Mancini, E., London, G., Mercadal, L., Fessy, H., Perrone, B., et al., 2008.
Patients with complex arrhythmias during and after haemodialysis suffer from
different regimens of potassium removal. Nephrol. Dial. Transplant. 23,
1415–1421.
chlaak, M.,  Theurich, S., Pickenhain, J., Skoetz, N., Kurschat, P., von
Bergwelt-Baildon, M.,  2013. Allogeneic stem cell transplantation for advanced
primary cutaneous T-cell lymphoma: a systematic review. Crit. Rev. Oncol.
Hematol. 85, 21–31.
ARGRETIN (bexarotene) capsules [package insert]. Bridgewater, NJ : Valeant
Pharmaceuticals Inc., 2013.alpur, R., Singh, L., Daulat, S., Liu, P., Seyfer, S., Trynosky, T., et al., 2012. Long-term
outcomes of 1263 patients with mycosis fungoides and Sézary syndrome from
1982 to 2009. Clin. Cancer Res. 18, 5051–5060.
an, J., Cang, S., Ma,  Y., Petrillo, R.L., Liu, D., 2010. Novel histone deacetylase
inhibitors in clinical trials as anti-cancer agents. J. Hematol. Oncol. 3 (5)./Hematology 106 (2016) 99–107 107
Tsambiras, P.E., Patel, S., Greene, J.N., Sandin, R.L., Vincent, A.L., 2001. Infectious
complications of cutaneous T-cell lymphoma. Cancer Control 8, 185–188.
VALCHLOR (mechlorethamine HCl) 0.02% gel [prescribing information]. Malvern,
PA: Ceptaris Therapeutics, Inc., 2012.
Vij, A., Duvic, M.,  2012. Prevalence and severity of pruritus in cutaneous T cell
lymphoma. Int. J. Dermatol. 51, 930–934.
Whittaker, S.J., Demierre, M.,  Kim, E.J., Rook, A.H., Lerner, A., Duvic, M., et al., 2010.
Final results from a multicenter, international, pivotal study of romidepsin in
refractory cutaneous T-cell lymphoma. J. Clin. Oncol. 28, 4485–4491.
Whittaker, S., Knobler, R., Ortiz, P., Vermeer, M.,  Karrasch, M.,  Hasan, B., et al., 2012.
Major achievements of the EORTC cutaneous lymphoma task force (CLTF). EJC
Suppl. 10, 46–50.
ZOLINZA (vorinostat) [package insert]. Whitehouse Station, NJ : Merck & Co., 2015.
Zackheim, H.S., McCalmont, T.H., 2002. Mycosis fungoides: the great imitator. J.
Am.  Acad. Dermatol. 47, 914–918.
Biography
Sunil A. Reddy is an attending physician at Stanford Cancer Institute (Stanford,
California). He serves as a Medical Oncologist in the cutaneous oncology program
and is involved in the care of Melanoma, Mycosis Fungoides/Sezary Syndrome, other
Non-Hodgkin’s Lymphomas and Merkel Cell Carcinoma. In addition to the above, heship  to Clinical Guidelines. He is also interested in immunotherapy and its optimal
use.
